Oral 8 items

Trials, agents, guidance

• Agent Muvalaplin (LY3473329)Phase 3 outcomes (MOVE-Lp(a), n=10,450, recruiting)
• Trial MOVE-Lp(a) (muvalaplin outcomes)Recruiting, primary completion March 2031
• Trial KRAKEN (muvalaplin phase 2)Completed, published JAMA 2025

Studies

• KRAKEN: oral muvalaplin lowers Lp(a) by 82 to 86 percent on an intact-particle assay (Nicholls et al., JAMA 2025)JAMA · January 2025 9
• Muvalaplin, the first oral inhibitor of Lp(a) formation: phase 1 (Nicholls et al., JAMA 2023)JAMA · September 2023 8
• Berberine lowers Lp(a) and apoB more in women than men, two randomised placebo-controlled trials (JACC Asia 2026)JACC Asia · July 2026 6
• Muvalaplin cuts Lp(a) by up to 86% in phase 2 without injection-site reactions, review (Cardiovasc Hematol Disord Drug Targets 2026)Cardiovasc Hematol Disord Drug Targets · January 2026 6

Video and podcasts

3:40

AHA 2024: KRAKEN, oral muvalaplin lowers Lp(a) by up to 85 percent (Stephen Nicholls)

Stephen J. Nicholls · November 2024